schedules for patients with any degree of renal impairment. The nonrenal clearance of cefsulodin was also noted to be significantly lower in groups II and III than in group I. Further investigations will be necessary to elucidate the mechanism(s) responsible for the decrease in the nonrenal clearance of cefsulodin.
The pharmacokinetic characteristics of cefsulodin after the administration of single intravenous doses to individuals with normal renal function have been described previously (5) . The kinetic behavior of cefsulodin in these patients is similar to that of cephalothin in that approximately 60%o of each drug is eliminated unchanged in the urine. However, the terminal half-life of cefsulodin is considerably longer than that reported for cephalothin (5, 6) . Since cefsulodin is primarily eliminated by urinary excretion, it would be expected that renal failure would prolong its elimination. Furthermore, since the metabolism of cephalothin has been reported to be decreased in patients with renal impairment, a further prolongation of the elimination of cefsulodin in uremic patients might be expected (7) . Available data on the kinetics of cefsulodin in patients with renal impairment are limited (3) . Therefore, this study was initiated to characterize the pharmacokinetics of cefsulodin in 19 patients with different levels of renal function.
MATERIALS AND Concentrations of cefsulodin in plasma were determined by high-pressure liquid chromatography (4) . The inter-and intra-assay coefficients of variation of the procedure are less than 4 and 2%, respectively. Data analysis. The decline in cefsulodin concentration in the plasma of each patient was clearly biexponential; therefore, the data were analyzed in terms of the following equation:
where C is the concentration in plasma at time t. A and B are the intercepts, and a and a are the disposition rates obtained from the first and second phases, respectively, of the plot of log cefsulodin concentration in plasma versus time.
Initial estimates of the parameters in the above equation were obtained by standard curve-stripping procedures. Final estimates were obtained by nonlinear regression analysis with the program KINA on a Control Data digital computer (University Computing Center, University of Minnesota, Minneapolis). All cefsulodin concentrations were weighted according to their reciprocal-squared concentrations during the computer fitting procedure. Since the cefsulodin doses were infused over a period of 30 min, the results of the computer analysis were analyzed with the appropriate equations for the biphasic decay of log concentration versus time after the termination of an intravenous infusion (9) .
The volume of distribution of the central compartment (Vdl), the steady-state volume of distribution (Vd35), the half-life of the a-and 3-phases (t0/2a and t'/2p, respectively), and the plasma clearance (Clp) were calculated by standard techniques (1). The area under the plasma concentration versus time curve to infinite time (AUCX) was calculated for each subject by the trapezoidal method.
The renal clearance (Clr) of each subject was calculated as: Fig. 1 . The biexponential decay of cefsulodin concentrations in plasma is evident in each case. Considerable differences in the rate at which cefsulodin disappeared from plasma in the three groups were noted; these differences correlated with the decline in renal function.
The 24-h cumulative urinary excretion of cefsulodin averaged 61.53% of the dose in subjects with normal renal function. This fraction declined to 33.5% in group II subjects and to less than 7% of the dose in subjects with severe renal impairment.
The pharmacokinetic parameters obtained from the three groups are shown in This study shows that the pharmacokinetic cefsulodin also decreased as renal function de-behavior of cefsulodin differs from those of clined (Fig. 2) . Although the Cl,s of cefsulodin many other cephalosporins (6) . After intravein groups II and III were statistically indistin-nous dosage, it distributes initially into an apparguishable (32.1 and 25.5 ml min-1, respectively), ent fluid volume equal to approximately 16% of it was significantly reduced in both of these total body weight and subsequently into a volgroups as compared with group I. ume equal to approximately 26% of total body Based on the observed correlations between weight. After distribution is complete, the plassome pharmacokinetic parameters and CLr, re-ma concentrations decline monoexponentially, gression analysis was used to obtain equations with a half-life of approximately 1.77 h in sub- jects with normal renal function. However, the Clp and Clr of cefsulodin are considerably smaller than those of most currently available cephalosporins. Furthermore, the ratio of Clr to ClCr was less than 1 in all subjects. Although sufficient data were not obtained to define the site(s) or mechanism(s) involved, this observation suggests that cefsulodin undergoes tubular reabsorption, since the protein binding of cefsulodin is approximately 15%. This finding contrasts with the glomerular filtration of free drug and active secretion of total drug characteristic of the Clr of other cephalosporins (6) .
Only 61.53% of the cefsulodin dose was recovered unchanged in the urine of subjects with normal renal function. This finding is comparable to the value of 60.4% reported by Granneman et al. (5) Creatinine Clearance (ml/mm) (2, 8) . Because of its simplicity and the combined benefits of less frequent drug administration and the assurance of attaining high peak drug concentrations, the prolongation of the maintenance dosing interval (-y) may be preferred. Regardless of which method is utilized, since Vd33 is not affected by renal failure, the loading dose in renal failure patients will be identical to that in normal subjects. The degree of alteration of y may then be calculated by utilizing the relationship between Clp and Clcr (Fig. 4) This yields a yfailure of approximately 1.9, 2.5, and 3.7 times the normal value for patients with Clcrs of 50, 30, and 10 ml min-1, respectively.
Our data demonstrate that the pharmacokinetic parameters of cefsulodin are markedly altered in patients with renal impairment. The Clp and Clr were significantly reduced in the patients with severe renal impairment, and the decline was linearly related to Clcr. The significant relationship between Clp and Clcr may be used to revise dosage schedules for patients with any degree of renal function impairment. The Clnr was also significantly lower in the patients with decreased renal function. However, further investigation will be necessary to determine the mechanism(s) responsible for this decrease.
